Azd 5991

Manufactured by MedChemExpress

Sourced in United States

AZD-5991 is a laboratory reagent manufactured by MedChemExpress. It is a small molecule that can be used for research purposes.

Automatically generated - may contain errors

Lab products found in correlation

4 protocols using azd 5991

Comprehensive Cell Line Treatment Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

EAC lines FLO-1, Eso26, and OE33 were purchased from the European Collection of Authenticated Cell Cultures via Sigma-Aldrich. Mesothelioma cell lines H28, H226, H2052, and H2452 were purchased from ATCC. All cell lines were authenticated yearly with HLA analysis and tested for Mycoplasma contamination every 6 months. Cells were cultured in RPMI (Thermo Fisher Scientific, 11875-093) with 10% FCS and 1% penicillin/streptomycin (Gibco No. 15140-122).
Cells were treated as described with Bcl-2 inhibitor, ABT199 (Apexbio; ref. 36 (link)), Bcl-xL inhibitor, A1155463 (MedChemExpress; ref. 37 ), or Mcl-1 inhibitor, S63845 (Active Biochem) and AZD-5991 (MedChemExpress; refs. 33, 38 (link)), and CDDP (APP Pharmaceuticals, NDC 63323-103-65).

Surman D.R., Xu Y., Lee M.J., Trepel J., Brown K., Ramineni M., Splawn T.G., Diggs L.P., Hodges H.C., Davis J.L., Lee H.S., Burt B.M, & Ripley R.T. (2021). Therapeutic Synergy in Esophageal Cancer and Mesothelioma Is Predicted by Dynamic BH3 Profiling. Molecular Cancer Therapeutics, 20(8), 1469-1480.

+ Open protocol

+ Expand

Antiapoptotic Protein Inhibition in Mesothelioma

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

EAC lines FLO-1, Eso26, and OE33 were purchased from European Collection of Authenticated Cell Cultures via Sigma Aldrich. Mesothelioma cell lines H28, H226, H2052, and H2452 were purchased from American Type Culture Collection. All cell lines were authenticated yearly with human leukocyte antigen (HLA) analysis and tested for mycoplasma contamination every six months. Cells were cultured in RPMI (ThermoFisher, 11875–093) with 10% fetal calf serum and 1% penicillin/streptomycin (Gibco #15140–122).
Cells were treated as described with Bcl-2 inhibitor, ABT199 (Apexbio)[36 (link)], Bcl-xL inhibitor, A1155463 (MedChemExpress)[37 ], or Mcl-1 inhibitor, S63845 (Active Biochem) and AZD-5991 (MedChemExpress) [33 (link), 38 (link)], and CDDP (APP Pharmaceuticals, NDC 63323–103-65).

+ Open protocol

+ Expand

Pharmacological Assessment of Potential Therapeutics

Check if the same lab product or an alternative is used in the 5 most similar protocols

Venetoclax, AZD-4320, Navitoclax, ABT-737, AZD-5991, 5-Azacytidine (5-Aza), Etoposide and MK-571 were purchased from MedChemExpress (USA). Midostaurin, Gilteritinib, Ivosidenib and Enasidenib were acquired from Selleck Chemicals (USA). Reversan was obtained from Merck (Germany). Ethacrynic acid (EA) was purchased from Sigma-Aldrich (USA). All compounds were diluted in DMSO. Buthionine sulfoximine (BSO) was purchased from Merck (Germany) and diluted in ddH₂O. For in vivo experiments, AZD-4320 was dissolved in 30% 2-Hydroxypropyl-β-cyclodextrin (HP-β-CD, Merck (Germany) solution in ddH₂O (3 mM stock).

Ebner J., Schmoellerl J., Piontek M., Manhart G., Troester S., Carter B.Z., Neubauer H., Moriggl R., Szakács G., Zuber J., Köcher T., Andreeff M., Sperr W.R., Valent P, & Grebien F. (2023). ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia. Nature Communications, 14, 5709.

+ Open protocol

+ Expand

Small Molecule Compound Acquisitions

Check if the same lab product or an alternative is used in the 5 most similar protocols

Gilteritinib, SCH772984, and AZD1480 were purchased from Selleck Chemicals (Houston, TX, USA). MRX-2843 and AZD5991 were purchased from MedChemExpress (Monmouth Junction, NJ, USA). 10058-F4 and Cytarabine (AraC) were purchased from AbMole Bioscience (Houston, TX, USA).

Wu S., Edwards H., Wang D., Liu S., Qiao X., Carter J., Wang Y., Taub J.W., Wang G, & Ge Y. (2022). Inhibition of Mcl-1 Synergistically Enhances the Antileukemic Activity of Gilteritinib and MRX-2843 in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia. Cells, 11(17), 2752.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!